glp-1 discovery A timeline of GLP- 1 and clinical development. Created in Mass spectrometry in the development

Lee HM, Napolitano S, Sorokin A, Woods MN, Chowdhury S, Alshenaifi JY, Singh AK, Shen JP, Meric-Bernstam F, Rai K, Kopetz S

It doesnt stay in your body very long and may require consistent dosing

Safety data indicate no major excess risk with combination therapy, although gastrointestinal effects and class-specific adverse events remain relevant

First, establishing interoperable data infrastructures that connect characterization, digestion, organ-on-chip, in vivo and clinical datasets for nanoencapsulated nutraceuticals would enable robust AI models and digital twins, and avoid repeated underpowered studies on isolated endpoints